BSX - Boston Scientific Corp Stock Price, Fair Value and News

74.94USD+0.68 (+0.92%)Market Closed

Market Summary

USD74.94+0.68

Market Closed

0.92%

BSX Alerts

1 major insider sales recently.

BSX Stock Price

View Fullscreen

BSX RSI Chart

BSX Valuation

Market Cap

110.2B

Price/Earnings (Trailing)

62.21

Price/Sales (Trailing)

7.49

EV/EBITDA

32.31

Price/Free Cashflow

64.89

BSX Price/Sales (Trailing)

BSX Profitability

EBT Margin

14.61%

Return on Equity

8.89%

Return on Assets

4.83%

Free Cashflow Yield

1.54%

BSX Fundamentals

BSX Revenue

Revenue (TTM)

14.7B

Rev. Growth (Yr)

13.78%

Rev. Growth (Qtr)

3.52%

BSX Earnings

Earnings (TTM)

1.8B

Earnings Growth (Yr)

57.01%

Earnings Growth (Qtr)

-2.18%

Breaking Down BSX Revenue

Last 7 days

-3.4%

Last 30 days

-2.8%

Last 90 days

2.4%

Trailing 12 Months

42.4%

How does BSX drawdown profile look like?

BSX Financial Health

Current Ratio

1.66

Debt/Equity

0.48

Debt/Cashflow

0.26

BSX Investor Care

Shares Dilution (1Y)

2.26%

Diluted EPS (TTM)

1.19

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	14.7B	0	0	0
2023	13.0B	13.4B	13.8B	14.2B
2022	12.2B	12.3B	12.6B	12.7B
2021	10.1B	11.2B	11.5B	11.9B
2020	10.8B	10.2B	10.1B	9.9B
2019	9.9B	10.1B	10.4B	10.7B
2018	9.3B	9.5B	9.7B	9.8B
2017	8.6B	8.7B	8.8B	9.0B
2016	7.7B	8.0B	8.2B	8.4B
2015	7.4B	7.3B	7.4B	7.5B
2014	7.2B	7.2B	7.3B	7.4B
2013	7.1B	7.1B	7.1B	7.1B
2012	7.6B	7.4B	7.3B	7.2B
2011	7.8B	7.8B	7.8B	7.6B
2010	8.1B	8.0B	7.9B	7.8B
2009	8.0B	8.1B	8.1B	8.2B
2008	0	8.3B	8.2B	8.1B
2007	0	0	0	8.4B

Get all data in R, Python etc through our Historical Stock Data APIs

About Boston Scientific Corp

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions. Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

CEO	Mr. Michael F. Mahoney
WEBSITE	bostonscientific.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	45000

Boston Scientific Corp Frequently Asked Questions

What is the ticker symbol for Boston Scientific Corp? What does BSX stand for in stocks?

BSX is the stock ticker symbol of Boston Scientific Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Boston Scientific Corp (BSX)?

As of Fri Jul 26 2024, market cap of Boston Scientific Corp is 110.18 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BSX stock?

You can check BSX's fair value in chart for subscribers.

Is Boston Scientific Corp a good stock to buy?

The fair value guage provides a quick view whether BSX is over valued or under valued. Whether Boston Scientific Corp is cheap or expensive depends on the assumptions which impact Boston Scientific Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BSX.

What is Boston Scientific Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, BSX's PE ratio (Price to Earnings) is 62.21 and Price to Sales (PS) ratio is 7.49. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BSX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Boston Scientific Corp's stock?

In the past 10 years, Boston Scientific Corp has provided 0.192 (multiply by 100 for percentage) rate of return.